EAS Consensus Panel (SAMS)
![Alirocumab shows benefit in SAMS with myotonic dystrophy](https://www.pcsk9forum.org/wp-content/uploads/articleplaceholder-150x150.jpg)
Alirocumab shows benefit in SAMS with myotonic dystrophy
There are currently few options for patients with statin intolerance and myotonic dystrophy. In this case report, a 74-year-old male with hypercholesterolaemia (serum LDL cholesterol 210 mg/dL), hypogonadism, insulin-controlled type 2 diabetes mellitus, and minimally elevated serum creatine kinase levels (184 U/L, ref. range 38-174),…
read more »Posted on 18 December 2017 |
Posted in News